Off your game?

Read our free Dr K report on how to optimize your mind and body so you can boost your focus when trading the markets.
Your email will always remain private.


VVUS received FDA advisory panel approval for its diet pill Exparel last February when it gapped up nearly 80% in one day. Yesterday, national newspaper USA Today prematurely reported that VVUS had received full FDA approval. VVUS sold off heavily when USA Today retracted the report.

Today, VVUS has indeed received full FDA approval so is gapping up premarket, qualifying it as a buyable gap up.

Exparel reduces or eliminates need for opiates to control post-surgical pain. The question will be how well VVUS can market it since Vicodin is such a household word, and many huge opiate manufacturers will compete with exparel. VVUS should see strong revenues as public awareness of the benefits of Exparel grows.

For those unfamiliar with our buyable gap-up trading strategy, type in 'gap' in the keyword search bar here: https://www.virtueofselfishinvesting.com/faqs

This information is provided by MoKa Investors, LLC DBA Virtue of Selfish Investing (VoSI) is issued solely for informational purposes and does not constitute an offer to sell or a solicitation of an offer to buy securities. Information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of available data. VoSI reports are intended to alert VoSI members to technical developments in certain securities that may or may not be actionable, only, and are not intended as recommendations. Past performance is not a guarantee, nor is it necessarily indicative, of future results. Opinions expressed herein are statements of our judgment as of the publication date and are subject to change without notice. Entities including but not limited to VoSI, its members, officers, directors, employees, customers, agents, and affiliates may have a position, long or short, in the securities referred to herein, and/or other related securities, and may increase or decrease such position or take a contra position. Additional information is available upon written request. This publication is for clients of Virtue of Selfish Investing. Reproduction without written permission is strictly prohibited and will be prosecuted to the full extent of the law. ©2018 MoKa Investors, LLC DBA Virtue of Selfish Investing. All rights reserved.
Copyright ©2018 MoKa Investors, LLC DBA Virtue of Selfish Investing.
All Rights Reserved.
privacy policy